KB Home
KBH
D.R. Horton
DHI
Lennar Corp
LEN
Meritage Homes
MTH
Ecopetrol
EC
US Stock MarketDetailed Quotes
TERN Terns Pharmaceuticals
- 3.630
- 0.0000.00%
Close Mar 6 16:00 ET
- 3.450
- -0.180-4.96%
Post 20:01 ET
308.33MMarket Cap-3.08P/E (TTM)
3.670High3.520Low669.88KVolume3.560Open3.630Pre Close2.42MTurnover1.30%Turnover RatioLossP/E (Static)84.94MShares11.40052wk High0.85P/B186.41MFloat Cap3.27152wk Low--Dividend TTM51.35MShs Float28.360Historical High--Div YieldTTM4.13%Amplitude1.450Historical Low3.605Avg Price1Lot Size
About Terns Pharmaceuticals Company
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-? agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.
Company Profile
SymbolTERN
Company NameTerns Pharmaceuticals
Listing DateFeb 5, 2021
Issue Price17.00
Founded2017
CEOMs. Amy Burroughs
MarketNASDAQ
Employees66
Fiscal Year Ends12-31
Address1065 East Hillsdale Boulevard,Suite 100
CityFoster City
ProvinceCalifornia
CountryUnited States of America
Zip Code94404
Phone1-650-525-5535
Websitehttp://www.ternspharma.com
Company Executives
- Name
- Position
- Salary
- Amy Burroughs
- Chief Executive Officer and Director
- --
- Andrew Gengos
- Chief Financial Officer
- --
- Melita Sun Jung
- Chief Business Officer
- --
- Elona Kogan
- Chief Legal Officer
- --
- David Eric Strauss
- Corporate Controller and Vice President, Finance
- --
- David Fellows
- Chairman of the Board
- 340.15K
- Dr. Emil T. Kuriakose, M.D.
- President and Head, Research and Development
- --
- Dr. Erin Quirk, M.D.
- President and Head of Research and Development
- 4.67M
- Heather D. Turner
- Director
- --
- Dr. Radhika Tripuraneni, M.D.,M.P.H.
- Director
- 303.06K
- Robert W. Azelby
- Director
- --
- Jill M. Quigley, Esq.
- Independent Director
- 306.14K
- Jeffrey B. Kindler, Esq.
- Independent Director
- 304.99K
- Dr. Hongbo Lu, PhD
- Independent Director
- 299.99K
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.